Trials / Conditions / Neoadjuvant Immunotherapy

Neoadjuvant Immunotherapy

18 registered clinical trials studyying Neoadjuvant Immunotherapy — 13 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab NCT07387198	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Not Yet Recruiting	A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, NCT07515469	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Not Yet Recruiting	Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in NCT07373899	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	—
Not Yet Recruiting	Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC NCT07231575	Sun Yat-sen University	Phase 2
Not Yet Recruiting	A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based NCT06977828	The First Affiliated Hospital with Nanjing Medical University	Phase 2
Withdrawn	Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer NCT06895941	Shanghai Pulmonary Hospital, Shanghai, China	—
Recruiting	Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer NCT06903858	Sun Yat-sen University	Phase 2
Active Not Recruiting	QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer NCT07205497	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
Recruiting	Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeuti NCT06926179	Peking University Cancer Hospital & Institute	—
Recruiting	Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC NCT06714708	Anhui Provincial Cancer Hospital	Phase 2
Recruiting	The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer NCT06623487	Ruijin Hospital	—
Not Yet Recruiting	Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer NCT06448169	Shandong University	—
Recruiting	Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preservin NCT06209294	Xiaohua Wu	Phase 2
Recruiting	Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-posi NCT05837806	Tianjin Medical University Second Hospital	Phase 2
Not Yet Recruiting	Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma NCT05270824	Fujian Medical University	Phase 3
Unknown	CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or NCT04913896	The First Hospital of Jilin University	—
Unknown	PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer NCT04815408	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
Unknown	Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma NCT05777707	Beijing Friendship Hospital	Phase 1 / Phase 2